Alpha Cognition (ACOG) vs Compugen (CGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Cognition (ACOG) has outperformed Compugen (CGEN) over the past year, gaining 23.0% versus a gain of 22.2%. Compugen is the larger company by market cap ($203.7 million vs $196.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | CGEN |
|---|---|---|
| Share price | $9.04 | $2.15 |
| Market cap | $196.87M | $203.66M |
| 1-day change | +0.67% | -3.15% |
| YTD return | +39.08% | +40.52% |
| 1-year return | +22.99% | +22.16% |
| 5-year return | — | -66.19% |
| P/E ratio (TTM) | — | 5.66 |
| EPS (TTM) | $-1.32 | $0.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.14 | $3.24 |
| 52-week low | $4.50 | $1.43 |
| Distance from 52-week high | -10.85% | -33.64% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.12% | +113.95% |
| Average volume | 126.03K | 247.77K |
| Shares outstanding | 21.78M | 94.72M |
| Employees | 71 | 75 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About Compugen
CGEN stock →Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Healthcare · Biotechnology · 75 employees
ACOG vs CGEN FAQ
Which is bigger, Alpha Cognition or Compugen?
Compugen (CGEN) is larger, with a market capitalization of $203.66M compared with $196.87M for Alpha Cognition (ACOG).
Which stock has performed better over the past year, ACOG or CGEN?
ACOG returned +22.99% over the past 12 months, compared with +22.16% for CGEN (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and Compugen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.